Therefore, it is tempting to speculate that MYC blockage confers responsiveness of HCC cells to cabozantinib by reducing the expression levels of MYC targets, thus providing a higher degree of dependency on MET signalling support. The gene discussed is MET; the disease is hepatocellular carcinoma.